Login/Register

WeChat

For more information, follow us on WeChat

Connect

For more information, contact us on WeChat

Email

You can contact us info@ringiertrade.com

Phone

Contact Us

86-21 6289-5533 x 269

Suggestions or Comments

86-20 2885 5256

Top

Shanghai Mediumbank Biotechnology Co., LTD.

Shanghai Mediumbank Biotechnology Co., LTD.

Industry involved:
Application industry:
Establishment Time:2019
Main Product:CHO Cell Platform、HEK293 Cell Platform、Stem Cell Platform、Insect Cell Platform、VERO Cell Platform
Company Website: Enter the official website
Area/Region:China

Company Introduction

Shanghai MediumBank Biotechnology Co., LTD. (MediumBank) , since its establishment, with professional experience and technical accumulation, MediumBank's products and services have covered CHO cells, HEK293 cells, insect cells, T cells/stem cells, Sp2/0 & NS0 cells, Vero cells and other major cell platforms, the performance of most products and services have reached the international leading level. In 2021, MediumBank's MFG1 production capacity, constructed to GMP standards, officially commenced production, the construction of the MFG2 mass production base continued to make progress. In 2022, the company flawlessly passed the ISO13485 quality system certification, achieving further upgrades in production management and quality systems. In 2023, MediumBank was awarded the title of " specialized, high-end and innovation-driven" completed quality audits by several Chinese listed biopharmaceutical companies, was the first to complete the DMF filing for the dual feed medium (MaxFA/FB), and successfully expanded several products to international markets.



Currently, MediumBank’s clients encompass a wide range of biopharmaceutical companies, including those focused on monoclonal antibodies, fusion proteins, vaccines for animals or humans, IVD, cell and gene therapies, and cultured meat. MediumBank's products and services have been validated by over 600+ biopharmaceutical companies worldwide, widely used in various stages of biopharmaceutical research and development, clinical filings, and commercial production, earning recognition, trust, and support from hundreds of companies in the industry..



Currently, MediumBank Biotech's clients encompass a wide range of biopharmaceutical companies, including those focused on monoclonal antibodies, fusion proteins, vaccines for animals or humans, IVD, cell and gene therapies, and cultured meat. MediumBank's products and services have been validated by over 600+ biopharmaceutical companies worldwide, widely used in various stages of biopharmaceutical research and development, clinical filings, and commercial production, earning recognition, trust, and support from hundreds of companies in the industry.



MediumBank makes bioprocessing much simpler and more efficient!